Scarica l'app Stockscreener
191.90
0.99%
-1.915
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
BIIB: Wedbush Raises Price Target to $187 While Maintaining Neut - GuruFocus
Mizuho Raises Price Target on Biogen to $236 From $207, Keeps Outperform Rating - marketscreener.com
Biogen Pipeline Advances In Lupus And SMA Reshape Growth Outlook - Yahoo Finance
State of Michigan Retirement System Has $6.04 Million Position in Biogen Inc. $BIIB - MarketBeat
Why Biogen (BIIB) Is Up 8.2% After Mixed 2025 Earnings and Neurology Pipeline Updates – And What's Next - Yahoo Finance
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China - ACN Newswire
Biogen Refocuses On High-Need Neurology As New Drugs Reach Inflection Point - simplywall.st
Analyst JP Morgan Raises Price Target for Biogen (BIIB) to $230 - GuruFocus
Biogen (BIIB) Sees Raised Price Target by Canaccord Genuity | BI - GuruFocus
Key facts: Analysts Boost Biogen Price Targets; Profit Outlook Improves; Leqembi Review Accelerated - TradingView
BIIB: BMO Capital Elevates Price Target While Maintaining Market Perform Rating | BIIB Stock News - GuruFocus
BIIB Analysts Maintain Rating, Significant Price Target Increase by TD Cowen | BIIB Stock News - GuruFocus
Biogen (NASDAQ:BIIB) Price Target Raised to $215.00 - MarketBeat
Biogen (BIIB) Analyst Rating Update: Citigroup Raises Price Targ - GuruFocus
Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says - marketscreener.com
Guggenheim Raises Price Target on Biogen (BIIB) to $246 | BIIB S - GuruFocus
Goldman Sachs reiterates Buy rating on Biogen stock amid Leqembi growth - Investing.com
BMO Capital raises Biogen stock price target to $196 on Spinraza potential - Investing.com
BIIB: RBC Capital Increases Biogen's Price Target to $233 on Sus - GuruFocus
Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification' - Benzinga
Piper Sandler Raises Price Target for Biogen (BIIB) to $177 | BI - GuruFocus
Wells Fargo Raises Biogen (BIIB) Price Target to $200 | BIIB Sto - GuruFocus
Truist Securities Raises Price Target for Biogen (BIIB) to $193 | BIIB Stock News - GuruFocus
Biogen stock price target raised to $215 from $175 at TD Cowen - Investing.com
Biogen stock price target raised to $233 from $217 at RBC Capital - Investing.com
Piper Sandler raises Biogen stock price target to $177 on Leqembi ramp - Investing.com
Biogen’s much anticipated Tau readout in Alzheimer’s will spur more questions - PharmaLive
BIIB Stock Receives Raised Price Target from HC Wainwright & Co. - GuruFocus
Wedbush Raises Price Target on Biogen to $187 From $178, Keeps Neutral Rating - marketscreener.com
Biogen’s Alisha Alaimo On The Company’s Next Big Commercial Build - Citeline News & Insights
Guggenheim raises Biogen stock price target to $246 on pipeline potential - Investing.com
Canaccord Genuity raises Biogen stock price target on strong Q4 results - Investing.com
Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
RBC Raises Price Target on Biogen to $233 From $217, Keeps Outperform Rating - marketscreener.com
Biogen stock price target raised to $228 from $194 at H.C. Wainwright - Investing.com
Morgan Stanley Raises Price Target on Biogen to $190 From $156, Keeps Equalweight Rating - marketscreener.com
Baird reiterates Outperform rating on Biogen stock, maintains $250 price target - Investing.com
Bernstein Adjusts Price Target on Biogen to $201 From $191, Maintains Market Perform Rating - marketscreener.com
Piper Sandler Adjusts Price Target on Biogen to $177 From $157, Maintains Neutral Rating - marketscreener.com
Citigroup Adjusts Price Target on Biogen to $215 From $185, Maintains Neutral Rating - marketscreener.com
Guggenheim Adjusts Price Target on Biogen to $246 From $185, Maintains Buy Rating - marketscreener.com
Biogen FY25 Earnings: Stable EPS, Amid Pressure From Multiple Sclerosis Franchise (BIIB) - Seeking Alpha
TD Cowen Adjusts Price Target on Biogen to $215 From $175, Maintains Buy Rating - marketscreener.com
Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi - Stocktwits
Analyst recommendations: Align, Take-Two, Biogen, PayPal, Stellantis… - marketscreener.com
The Truth About Biogen Inc: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Biogen says biologics license application for subcutaneous formulation of Leqembi for treatment of early Alzheimer's disease designated for Priority Review in China - marketscreener.com
Biogen Says Biologics License Application For Subcutaneous Formulation Of Leqembi For Treatment Of Early Alzheimer’S Disease Designated For Priority Review In China - TradingView
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China - Biogen
Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump - AOL.com
Biogen (BIIB) Q4 Loss And Margin Compression Reinforce Bearish Profitability Narratives - simplywall.st
Multiple Sclerosis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion - Barchart.com
Lupin receives tentative US FDA approval for Dimethyl Fumarate Delayed Release Capsules, 120 mg and 240 mgn - lupin.com
Biogen Jumped 8% on Pipeline Win: Path to $260 in 2026 - TIKR.com
Biogen Inc. (NASDAQ:BIIB) Q4 2025 Earnings Call Transcript - Insider Monkey
Biogen Shares Rise on Q4 Earnings Beat Despite Lower Revenue Outlook - AlphaStreet News -
Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% - AlphaStreet News -
BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds - Finviz
Biogen Trial Updates Test Investor Views On Pipeline Strength And Valuation - simplywall.st
Decoding Biogen Inc (BIIB): A Strategic SWOT Insight - GuruFocus
Why Biogen Stock Surged Almost 9% Higher on Friday - Yahoo Finance
Biogen Earnings Call: Solid 2025, Cautious 2026 Outlook - TipRanks
Biogen Forecasts 2026 Revenue Decline, But Growth Prospects On The Horizon - Citeline News & Insights
Biogen’s Nusinersen Data And FDA Review Put Valuation In Focus - Yahoo Finance
Biogen Inc (BIIB) Q4 2025 Earnings Call Highlights: Strong Growt - GuruFocus
Biogen Holds on to Leqembi Lead in Overall Anti-Amyloid Market, Bolstered by Maintenance Indication - Precision Medicine Online
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Inc (BIIB) Q4 2025 Earnings Call Highlights: Strong Growth in Key Products Amidst Revenue Challenges - GuruFocus
How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat - Investor's Business Daily
Biogen stock pops, Robinhood gets lift as bitcoin ticks up - Yahoo Finance
Vumerity bucks the MS trend as Biogen provides upbeat profit forecast - FirstWord Pharma
Oppenheimer raises Biogen stock price target to $250 on long-term growth outlook - Investing.com
1.92%
1.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):